Notification That Annual Report Will Be Submitted Late (nt 10-k)
14 Giugno 2019 - 7:00PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
12b-25
|
SEC FILE NUMBER
001 – 15697
|
NOTIFICATION OF LATE FILING
(Check One):
|
☒
Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form
10-Q ☐ Form 10-D
|
|
☐ Form N-SAR ☐ Form N-CSR
|
|
For Period Ended:
March 31, 2019
|
|
☐
|
Transition Report on
Form 10-K
|
|
|
|
|
☐
|
Transition Report on Form 20-F
|
|
|
|
|
☐
|
Transition Report on Form 11-K
|
|
|
|
|
☐
|
Transition Report on Form 10-Q
|
|
|
|
|
☐
|
Transition Report on Form N-SAR
|
|
|
|
|
For
|
the Transition Period Ended: _____________________________________________
|
Read instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
|
If the notification relates to a portion of the filing checked
above, identify the Item(s) to which the notification relates:
PART I - REGISTRANT INFORMATION
Elite Pharmaceuticals, Inc.
Full name of registrant:
Former
name if applicable:
165 Ludlow Avenue
Address of Principal Executive Office (
Street and Number
)
Northvale, New Jersey 07647
City, state and zip code
PART II - RULES 12b-25(b) AND (c)
If the subject report
could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following
should be completed. (Check box if appropriate.)
|
(a)
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or
expense;
|
|
|
☒
|
(b)
The subject annual report, semi-annual report, transition report on Form 10-K, 20-F, 11-K, Form N-SAR or Form N-CSR, or
portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject
quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be
filed on or before the fifth calendar day following the prescribed due date; and
|
|
|
|
(c)
The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART III - NARRATIVE
State below in reasonable
detail why Form 10-K, 11-K, 20-F, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within
the prescribed time period.
The Registrant’s
Annual Report on Form 10-K for the period ended March 31, 2019 cannot be filed within the prescribed time period without unreasonable
effort or expense because of a delay by the Registrant in obtaining and compiling information relating to the Registrant’s
assessment of a material weakness in internal controls and required to be included in the Registrant’s Form 10-K.
PART IV - OTHER INFORMATION
(1)
|
Name and telephone number of person to contact in regard
to this notification
|
|
Carter Ward
|
|
(201)
|
|
367-7855
|
|
(Name)
|
|
(Area Code)
|
|
(Telephone Number)
|
(2)
|
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act
of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If answer is no, identify report(s).
|
☒ Yes ☐ No
(3)
|
Is it anticipated that any significant changes in results of operations from the corresponding
period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
|
☒ Yes ☐ No
If so, attach an explanation of the anticipated
change, both narratively and quantitatively, and, if appropriate, reasons why a reasonable estimate of the results cannot be made.
Total revenues for the
year ended March 31, 2019 are expected to increase by approximately $0.1 million or 1%, to approximately $7.6 million, as compared
to $7.5 million, for the corresponding period of the prior year.
Loss from operations
for the year ended March 31, 2019 is expected to increase by approximately $0.1 million or 1% to approximately $9.2 million as
compared to $9.1 million for the corresponding period of the prior year.
Net other income/expenses
for the year ended March 31, 2019 is expected to be a net other expense of approximately $0.8 million, as compared to a net other
income of $4.3 million for the comparable period of the prior year. This represents an increase in non-operating expense of approximately
$5.1 million for the year ended March 31, 2019, as compared to the comparable period of the prior year. The most significant component
in this increase in net non-operating expenses was the income recognized in relation to the change in fair value of derivative
instruments, which is a component of non-operating income/expenses and is expected to be approximately $0.2 million for the year
ended March 31, 2019, as compared to $4.7 million for the comparable period of the prior year.
Net loss attributable
to common shareholders is expected to increase by approximately $5.6 million to approximately $9.3 million for the year ended March
31, 2019 as compared to a net loss attributable to common shareholders of $3.7 million for the comparable period of the prior year.
Basic loss per share
is expected to be $0.01 on a weighted average shares outstanding of approximately 814 million shares. Basic loss per share for
the comparable period of the prior year was $0.00 on a weighted average shares outstanding of 796 million.
The Company's management
has concluded that material weaknesses in the Company’s internal controls over financial report existed. A material weakness
is a deficiency, or a combination of deficiencies, in internal controls over financial reporting such that there is a reasonable
possibility that a material misstatement of the Company's annual or interim financial statements will not be prevented or detected
on a timely basis.
The auditor’s
opinion on the Company’s financial statements for the year ended March 31, 2019 is expected to contain an explanatory paragraph
with respect to there being substantial doubt as to the Company’s ability to continue as a going concern and the Company
expects to continue to incur losses until it is able to generate sufficient revenues to support its operations and offset operating
costs.
Elite Pharmaceuticals, Inc.
(Name of Registrant
as Specified in Charter)
has caused this notification to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated:
June 14, 2019
|
By:
|
/s/ Carter J. Ward
|
|
|
Name:
Carter J. Ward
|
|
|
Chief Financial Officer
|
INSTRUCTION: The form
may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the
person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant
by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf
of the registrant shall be filed with the form.
ATTENTION
Intentional misstatements or omissions of
fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).
|
4
Grafico Azioni Elite Pharmaceuticals (QB) (USOTC:ELTP)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Elite Pharmaceuticals (QB) (USOTC:ELTP)
Storico
Da Nov 2023 a Nov 2024